Ensysce Biosciences presents at PainWeek, joins FDA psychedelics hearing

Ensysce Biosciences, Inc. (NASDAQ: ENSC), a clinical-stage biotechnology company, hosted a symposium at PainWeek 2026 attended by more than 320 pain management professionals, according to a company press release.

Dr. Jeff Gudin presented on the company's program to develop opioids for severe pain and provided background on Complex Regional Pain Syndrome Type 1 (CRPS). Dr. Richard Langford outlined Ensysce's approach to CRPS, including a platform added through the company's acquisition of Cy Biopharma.

Following PainWeek, a team from Ensysce attended an FDA hearing on psychedelic drug regulation. The hearing covered regulatory frameworks, professional training and credentialing, patient safety, and real-world data collection related to therapeutic psychedelic drug use. Dr. Langford spoke during a session on data collection and access considerations, addressing the role of interventional pain physicians in delivering psychedelic treatments.

"The FDA's hearing provided a substantial voice to the public for the FDA's understanding of psychedelic-based medicines, their use, access and the training of individuals involved with the treatment," said Lynn Kirkpatrick, Ph.D., Chief Executive Officer of Ensysce Biosciences. She added that the company is moving toward implementation of a Phase 2 clinical trial.

You May Also Be Interested In

• Coca-Cola picks Omnicom for North America, keeps WPP globally
• Kenorland Minerals plans $11M private placement at $2.10 per share
• Rambus invests in ChipAgents, adopts its AI chip design platform